Neutral impactStocks
ICICI Pru Nifty Pharma Index Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
Univest 5 hrs ago·18 Sept 2026, 3:28 am
The ICICI Pru Nifty Pharma Index Fund Direct Growth is a passive investment option that tracks the performance of the Nifty Pharma Index. By holding a basket of leading pharmaceutical companies, it offers investors exposure to the sector without the need to pick individual stocks. The fund aims to mirror the index's returns, making it a cost-effective way to gain broad market access to the healthcare and drug manufacturing industries.
This fund matters to investors looking for diversification within the healthcare sector. Since it is a direct growth plan, it carries lower expense ratios compared to regular plans, potentially enhancing long-term returns. However, as a sector-specific fund, it is subject to volatility driven by regulatory changes, patent expiries, and global health trends. Investors should consider their risk appetite before allocating capital.
What to watch next includes the fund's expense ratio, tracking error, and the performance of its top holdings. Monitoring the Nifty Pharma Index's movement and the fund's dividend distribution policy will also help in making informed decisions. Ensure this aligns with your long-term financial goals before investing.
Excerpt from Univest
Updated: 18 Sept 2026 • 9:01 am ICICI Pru Nifty Pharma Index Fund Direct Growth Plan is at a NAV of ₹20.5831 as of 17 Sep 2026, with scheme AUM of ₹156 Cr. Its 1-year, 3-year and 5-year returns are 17.57%, 18.84% and 0%, and the fund is tagged High Risk. In our view, it suits investors who want focused pharma exposure…Read the original at Univest
Key takeaways
- Category: Stocks.
Why it matters
A routine update. Use the price and stock snapshot to gauge how the market is responding.
